Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 15/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 15/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3219706 | 0.92 | CHRM3 (0.45) | CHRM3CHRM2CYP2D6KCNH2CHRM1 | |
| SCHEMBL3213540 | 0.89 | CHRM3 (0.46) | CHRM3CHRM2CYP2D6KCNH2CHRM1 | |
| SCHEMBL3210034 | 0.89 | CHRM2 (0.49) | CHRM3CHRM2CYP2D6KCNH2CHRM1 | |
| SCHEMBL3224624 | 0.82 | POLB (0.52) | CHRM3CHRM2CYP2D6KCNH2CHRM1 | |
| SCHEMBL3224057 | 0.82 | POLB (0.52) | CHRM3CHRM2CYP2D6KCNH2CHRM1 | |
| SCHEMBL3226484 | 0.81 | CHRM3 (0.44) | CHRM3CHRM2CYP2D6KCNH2CHRM1 | |
| SCHEMBL3224771 | 0.81 | CHRM2 (0.47) | CHRM3CHRM2CYP2D6KCNH2CHRM1 | |
| SCHEMBL3216742 | 0.80 | CHRM3 (0.46) | CHRM3CHRM2CYP2D6KCNH2CHRM1 | |
| SCHEMBL3216719 | 0.80 | CHRM3 (0.61) | CHRM3HRH1 | |
| SCHEMBL3216726 | 0.79 | ALDH1A1 (0.49) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | claimed |
| EP-2059505-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2009-05-20 | — | — | EP | claimed |
| WO-2008029349-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-13 | — | — | WO | claimed |
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
| EP-2059505-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008029349-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CYP2D6 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.